+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hcv clearance from saliva of hiv-hcv coinfected patients on treatment with interferon plus ribavirin

Hcv clearance from saliva of hiv-hcv coinfected patients on treatment with interferon plus ribavirin

To determine hepatitis C virus (HCV) RNA clearance from blood and saliva of HIV-HCV coinfected patients undergoing combined therapy with pegylated interferon plus ribavirin (PEG-IFN-RIB).Subjects and methodsStudy group was fromed of 60 HIV infected patients with chronic hepatitis C who were starting treatment with PEG-IFN-RIB. Blood and saliva samples were taken at baseline, at the end of treatment and 24 and 48 weeks latter. A nested RT-PCR technique was used to detect HCV-RNA in saliva. HCV-RNA was detected in saliva at baseline in 64.7% of patients. Thirty-four patients completed follow-up. The response rate (undetectable HCV RNA) in blood was 79.4% at the end of treatment; 55.8% at 24 weeks after the end of treatment and 50% at 48 weeks. HCV was detected in saliva of 13 (38.2%) patients at the end of treatment and in 18 (52.9%) patients at 24 and 48 weeks latter. Concordance of HCV clearance from blood and saliva reached its maximum value at 48 weeks after the end of treatment (odds ratio, 112.51). In HIV-HCV coinfected patients responders to PEG-IFN-RIB, the salivary glands do not appear to be a sanctuary site for HCV, although viral clearance from saliva may be slower than from blood.This article is protected by copyright. All rights reserved.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036847962

Download citation: RISBibTeXText

DOI: 10.1111/odi.12116

Related references

HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin. Oral Diseases 20(3): 313-318, 2014

Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients. Enfermedades Infecciosas Y Microbiologia Clinica 24(3): 213-214, 2006

Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). European Journal of Gastroenterology and Hepatology 28(9): 1003-1007, 2016

Clinical implications of the slower clearance of HCV-RNA under interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 327, 2003

Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. Aids Research and Human Retroviruses 28(9): 989-993, 2012

Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance. Journal of Acquired Immune Deficiency Syndromes 69(3): 286-290, 2015

HCV clearance patterns in saliva and serum of patients with chronic HCV infection under interferon plus ribavirin therapy. Journal of Oral Pathology and Medicine 34(5): 308-311, 2005

Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antiviral Therapy 9(4): 505-509, 2004

HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin. Journal of Hepatology 43(5): 783-790, 2005

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection 53(1): 36-42, 2006

Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antiviral Therapy 15(3): 333-342, 2010

CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients. HIV Medicine 11(3): 161-169, 2010

Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin. Revista Da Sociedade Brasileira de Medicina Tropical 40(6): 678-680, 2008

Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients. Arquivos de Gastroenterologia 46(2): 132-137, 2009

Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. Aids Research and Human Retroviruses 29(9): 1190-1194, 2013